FDA-cleared profile

Aquilion Precision (TSX-304A/1 and /2) V8.8 with AiCE

Canon Medical Systems Corporation

Aquilion Precision is an ultra-high-resolution whole-body CT system; AiCE deep-convolutional reconstruction reduces noise and improves image quality for abdomen and pelvis applications.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Aquilion Precision is an ultra-high-resolution whole-body CT system; AiCE deep-convolutional reconstruction reduces noise and improves image quality for abdomen and pelvis applications.
FDA source Exact FDA submission Checked 2026-09-03
Intended users
Qualified CT technologists and trained physicians.
FDA source Exact FDA submission Checked 2026-09-03
Care setting and population
Diagnostic CT departments requiring whole-body and ultra-high-resolution CT.
FDA source Exact FDA submission Checked 2026-09-03
Workflow role
CT acquisition and reconstruction, with AiCE for 1024 by 1024 high- and super-high-resolution abdomen and pelvis images.
Public source Exact FDA submission Checked 2026-09-03
Required input
X-ray projection data acquired by the 160-row, 0.25 mm detector under supported protocols.
FDA source Exact FDA submission Checked 2026-09-03
Output and human action
Cross-sectional whole-body CT volumes and AiCE-reconstructed abdomen or pelvis images.
FDA source Exact FDA submission Checked 2026-09-03
Limitations
AiCE is limited in K182901 to abdomen and pelvis, despite whole-body use of other reconstruction methods. Reported phantom improvements at matched dose do not establish dose reduction, diagnostic accuracy, or patient outcomes for every protocol.
FDA source Exact FDA submission Checked 2026-09-03

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K182901
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA
FDA source Exact FDA submission Checked 2026-09-03
Anatomy
Multi-region
FDA source Exact FDA submission Checked 2026-09-03
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2019-07-05
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Installed scanner reconstruction and DICOM workflow; validate protocol, matrix, reconstruction label, quantitative values, PACS presentation, and downstream compatibility.
Public source Exact FDA submission Checked 2026-09-03
Deployment and data flow
Ultra-high-resolution CT scanner with gantry, couch, console, 160-row detector, and V8.8 reconstruction software.
Public source Exact FDA submission Checked 2026-09-03
Security and privacy
K182901 states that cybersecurity documentation was included but does not publicly establish the implemented controls. Obtain the exact architecture, interfaces, identity, audit, encryption, patching, remote service, backup, and incident-response evidence.
FDA source Exact FDA submission Checked 2026-09-03

Confirm the controls against the exact contracted architecture and release.

Training and support
Only qualified ct technologists and trained physicians. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-03
Monitoring and change control
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: AiCE is limited in K182901 to abdomen and pelvis, despite whole-body use of other reconstruction methods. Reported phantom improvements at matched dose do not establish dose reduction, diagnostic accuracy, or patient outcomes for every protocol.
Public source Exact FDA submission Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K182901 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Installed scanner reconstruction and DICOM workflow; validate protocol, matrix, reconstruction label, quantitative values, PACS presentation, and downstream compatibility.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. AiCE is limited in K182901 to abdomen and pelvis, despite whole-body use of other reconstruction methods. Reported phantom improvements at matched dose do not establish dose reduction, diagnostic accuracy, or patient outcomes for every protocol.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: AiCE is limited in K182901 to abdomen and pelvis, despite whole-body use of other reconstruction methods. Reported phantom improvements at matched dose do not establish dose reduction, diagnostic accuracy, or patient outcomes for every protocol.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K182901 reports phantom image-quality testing and representative radiologist review. At matched dose, AiCE showed 13% improved low-contrast detectability and 42% noise reduction for super-high-resolution body imaging versus AIDR 3D, with an 8.8 lp/cm high-contrast spatial-resolution claim at 10% MTF.
Public source Exact FDA submission Checked 2026-09-03
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Low-contrast detectability improvement

13 %

AiCE versus AIDR 3D at matched dose in Aquilion Precision (TSX-304A/1 and /2) V8.8 with AiCE.

Tested version: Aquilion Precision TSX-304A/1 and /2 V8.8 with AiCE

Noise reduction

42 %

Super-high-resolution body AiCE versus AIDR 3D at matched dose in Aquilion Precision (TSX-304A/1 and /2) V8.8 with AiCE.

Tested version: Aquilion Precision TSX-304A/1 and /2 V8.8 with AiCE

High-contrast spatial resolution

8.8 lp/cm

10% modulation transfer function for abdomen/body in Aquilion Precision (TSX-304A/1 and /2) V8.8 with AiCE.

Tested version: Aquilion Precision TSX-304A/1 and /2 V8.8 with AiCE

K182901 FDA performance package for Aquilion Precision (TSX-304A/1 and /2) V8.8 with AiCE

Manufacturer phantom image-quality evaluation and board-certified radiologist review of representative abdomen and pelvis images · Abdomen and pelvis CT protocols on Aquilion Precision V8.8

exact submission · Tested version: Aquilion Precision TSX-304A/1 and /2 V8.8 with AiCE · Sponsor or vendor study

K182901

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-03

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
Public source Not applicable Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K182901 by exact submission identifier.
Public source Exact FDA submission Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
24Fields reviewed
8Source classes checked
20Unreviewed PubMed leads
10Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA materials, current product-family sources, selected clinical literature, reimbursement context, and exact-identifier recall candidates were reviewed. Pricing, contracted services, enabled options, final security architecture, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 20 PubMed and 10 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-03.

Alternatives

Related tools to compare

FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and...

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K232491

CT 5300

Philips Healthcare (Suzhou) Co., Ltd.

CT 5300 acquires head and whole-body cross-sectional CT images for diagnosis in adult and pediatric patients and supports low-dose lung-cancer screening under approved protocols.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2024-05-03